Author:
Zhang Xintong,Barnett Edward,Smith Jim,Wilkinson Emma,Subramaniam Rathan M.,Zarrabi Amir,Rodger Euan J.,Chatterjee Aniruddha
Reference120 articles.
1. The molecular taxonomy of primary prostate cancer;Abeshouse;Cell,2015
2. The diagnostic value of PET/CT imaging with the 68 Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer;Afshar-Oromieh;European Journal of Nuclear Medicine and Molecular Imaging,2015
3. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: A multi-institutional prospective study;Aggarwal;Journal of Clinical Oncology,2018
4. Neuroendocrine prostate cancer: Subtypes, biology, and clinical outcomes;Aggarwal;Journal of the National Comprehensive Cancer Network,2014
5. Aggarwal, R. R., Aparicio, A., Heidenreich, A., Sandhu, S. K., Zhang, Y., Salvati, M., … Hashemi Sadraei, N. (2021). Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTEimmune-oncology therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC). Wolters Kluwer Health.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献